Prevail Therapeutics to Highlight Multiple CNS-Focused Gene Therapy Programs at 2020 American Society of Gene & Cell Therapy Annual Meeting

29 Apr 2020 - Yahoo News
Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases Company Provides Design.
usx:prvl

---

Prevail Therapeutics Inc. (PRVL) Shares March Higher, Can It Continue?

22 Apr 2020 - Yahoo News
As of late, it has definitely been a great time to be an investor in Prevail Therapeutics Inc. (PRVL).
usx:prvl

---

Why Prevail Therapeutics (PRVL) Stock Might be a Great Pick

16 Apr 2020 - Yahoo News
Prevail Therapeutics (PRVL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
usx:prvl

---

Prevail Therapeutics to Present at AAT-AD/PD Focus Meeting 2020: Advances in Alzheimer’s and Parkinson’s Therapies

31 Mar 2020 - Yahoo News
Design of PROPEL Phase 1/2 Clinical Trial for Parkinson’s Disease Patients with GBA1 Mutations to Be Presented Preclinical Data of PR001 for Parkinson’s Disease with GBA1.
usx:prvl

---

Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

26 Mar 2020 - Yahoo News
Dosing Initiated in PROPEL Phase 1/2 Trial of PR001 for Treatment of Parkinson’s Disease with GBA1 Mutations Preparations Underway to Initiate PROVIDE Phase 1/2 Trial of.
usx:prvl

---

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN Mutation

24 Mar 2020 - Yahoo News
Prevail Therapeutics Inc. (PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the Company’s experimental ...
usx:prvl

---

Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutations

3 Mar 2020 - Yahoo News
Prevail Therapeutics Inc. (PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, provided an update today on the clinical advancement of its gene therapy program PR001 for patients with Parkinson’s disease with GBA1 ...
usx:prvl

---

Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation

2 Mar 2020 - Yahoo News
Prevail Therapeutics Inc. (PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application ...
usx:prvl

---

Prevail Therapeutics to Present at Upcoming Conferences

21 Feb 2020 - Yahoo News
NEW YORK, Feb. 21, 2020 -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based.
usx:prvl

---

The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

13 Feb 2020 - Yahoo News
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
usx:prvl

---